Diabetes research and clinical practice · 2026
Health-related quality of life and management routine in painful and painless diabetic polyneuropathy (PREDIP study).
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ziegler Dan, Fietz Charlotte, Keuthage Winfried, Lobmann Ralf, Rett Kristian, Reule Claudia, Rudolf Simone, Scheper Nikolaus, Schnell Oliver, Serban Pavel Marcel, Sjomin Janna, Stirban Ovidiu Alin, Strom Alexander, Ströhl Julia, Jaghutriz Benjamin Assad
Аннотация
AIMS: This non-interventional, prospective, multicenter registry study aimed to assess the real-world management routine and the impact of the severity of neuropathic pain on health-related quality of life in people with diabetic sensorimotor polyneuropathy (DSPN).
METHODS: Participants with possible/probable DSPN (n = 617) from practices or clinics were classified by the numerical pain rating scale into severe/moderate painful DSPN (Group 1;n = 262), mild painful DSPN (Group 2;n = 210), and painless DSPN (Group 3;n = 145). Mandatory assessment of DSPN included pain scales/questionnaires and the Short Form 12 Health Survey (SF-12), while optional assessment comprised point-of-care screening tools.
RESULTS: In Group 1, 42% of participants received any pharmacotherapy and 28% received analgesic pharmacotherapy for DSPN. Three different DSPN screening tools were used in 77%, 54%, and 28% of the participants. In multivariate analyses, decreased scores of the physical and mental SF-12 components were most consistently associated with both severe/moderate and mild painful DSPN compared to painless DSPN (P < 0.05). Severe/moderate painful DSPN was also associated with female sex, higher BMI, and longer diabetes duration (P < 0.05).
CONCLUSIONS: Although not only severe/moderate but also mild neuropathic pain are powerful risk factors of reduced health-related quality of life, painful DSPN still remains undertreated, whilst screening tools are underutilized in real-world practice.
METHODS: Participants with possible/probable DSPN (n = 617) from practices or clinics were classified by the numerical pain rating scale into severe/moderate painful DSPN (Group 1;n = 262), mild painful DSPN (Group 2;n = 210), and painless DSPN (Group 3;n = 145). Mandatory assessment of DSPN included pain scales/questionnaires and the Short Form 12 Health Survey (SF-12), while optional assessment comprised point-of-care screening tools.
RESULTS: In Group 1, 42% of participants received any pharmacotherapy and 28% received analgesic pharmacotherapy for DSPN. Three different DSPN screening tools were used in 77%, 54%, and 28% of the participants. In multivariate analyses, decreased scores of the physical and mental SF-12 components were most consistently associated with both severe/moderate and mild painful DSPN compared to painless DSPN (P < 0.05). Severe/moderate painful DSPN was also associated with female sex, higher BMI, and longer diabetes duration (P < 0.05).
CONCLUSIONS: Although not only severe/moderate but also mild neuropathic pain are powerful risk factors of reduced health-related quality of life, painful DSPN still remains undertreated, whilst screening tools are underutilized in real-world practice.